We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ibrexafungerp

News List

FDA Approves Brexafemme (ibrexafungerp) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections drugs
June 03, 2021
Scynexis, Inc. (NASDAQ: SCYX) today announced that FDA has approved Brexafemme (ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection.
SCYNEXIS Announces Positive Results of Oral Ibrexafungerp to Treat Severe Fungal Infections americanpharmaceuticalreview
March 05, 2021
SCYNEXIS announced positive results from the third interim efficacy analysis of the ongoing open-label Phase 3 FURI study and the first interim analysis of the ongoing open-label Phase 3 CARES study.
SCYNEXIS Announces Positive Results from Ibrexafungerp Study americanpharmaceuticalreview
January 13, 2020
SCYNEXIS announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study. The study is evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and ...